Diane M Harper

List of Publications by Year
in descending order

139 papers	15,443 citations	94433 37 h-index	20961 115 g-index
144 all docs	144 docs citations	144 times ranked	10912 citing authors

#	Article	IF	Citations
1	Implementation of INHERET, an Online Family History and Cancer Risk Interpretation Program for Primary Care and Specialty Clinics. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 63-70.	4.9	4
2	Concordant physician-patient characteristics lose importance for Arab American women and their healthcare- cross-sectional study. The Lancet Regional Health Americas, 2022, 10, 100225.	2.6	2
3	Comparative predictors for cervical cancer screening in Southeast Michigan for Middle Eastern-North African (MENA), White and African American/black women. Preventive Medicine, 2022, , 107054.	3.4	5
4	Vasectomy Training in Family Medicine Residency Programs: A National Survey of Residency Program Directors. Family Medicine, 2022, 54, 438-443.	0.5	0
5	Annual HIV screening rates for HIV-negative men who have sex with men in primary care. PLoS ONE, 2022, 17, e0266747.	2.5	2
6	The future of cancer screening after COVIDâ€19 may be at home. Cancer, 2021, 127, 498-503.	4.1	51
7	Disability Policies and Practices in Family Medicine Residencies: A CERA Study. Family Medicine, 2021, 53, 211-214.	0.5	2
8	Predictors of Human Papillomavirus Seropositivity in Appalachian Women Aged 18 to 26 Years. Sexually Transmitted Diseases, 2021, 48, 693-699.	1.7	0
9	HPV Vaccination Among Young Adults in the US. JAMA - Journal of the American Medical Association, 2021, 325, 1673.	7.4	25
10	Health-Related Quality of Life for People With Acute and Chronic Illnesses During the COVID-19 Pandemic. Journal of the American Board of Family Medicine, 2021, 34, 509-521.	1.5	11
11	Prevalence, Plans, and Perceptions: Disability in Family Medicine Residencies. Family Medicine, 2021, 53, 338-346.	0.5	6
12	Family Medicine Residentsâ€™ Experience During Early Phases of the COVID-19 Pandemic. PRiMER (Leawood,) Tj ETQq0 0 0 rgBT /Overl	0.6	3
13	Rigorous review and editorial oversight of clinical preprints. ELife, 2021, 10, .	6.0	2
14	Family Medicine Researchersâ€"Why? Who? How? When?. Family Medicine, 2021, 53, 647-649.	0.5	2
15	Predictors of screening for cervical and colorectal cancer in women 50â€"65Âyears old in a multi-ethnic population. Preventive Medicine Reports, 2021, 22, 101375.	1.8	10
16	Cancer risk perception and physician communication behaviors on cervical cancer and colorectal cancer screening. ELife, 2021, 10, .	6.0	12
17	Annual Wellness Visits for Persons With Physical Disabilities Before and After ACA Implementation. Annals of Family Medicine, 2021, 19, 484-491.	1.9	0
18	Elimination of cervical cancer depends on HPV vaccination and primary HPV screening. Lancet Infectious Diseases, The, 2021, 21, 1342-1344.	9.1	4

#	Article	IF	Citations
19	Streamlining the WHO cervical cancer elimination goal. Lancet Oncology, The, 2021, 22, 1484-1485.	10.7	1
20	Patient-Centered Home Cancer Screening Attitudes During COVID-19 Pandemic. Journal of Patient-centered Research and Reviews, 2021, 8, 340-346.	0.9	7
21	Transgender Education in North American Family Medicine Clerkships: A CERA Study. Family Medicine, 2021, 53, 676-683.	0.5	1
22	Three large scale surveys highlight the complexity of cervical cancer under-screening among women 45â€“65 years of age in the United States. Preventive Medicine, 2020, 130, 105880.	3.4	27
23	The vaginal microbiota, high-risk human papillomavirus infection, and cervical cytology: results from a population-based study. Gynecology and Pelvic Medicine, 2020, 3, 18-18.	0.1	4
24	HPV vaccination bridges to HPV screening. EClinicalMedicine, 2020, 23, 100435.	7.1	0
25	Awareness and Attitudes Around the New Subspecialty Within Ob/Gyn Called Complex Family Planning: A CERA Survey of Family Medicine Chairs. Family Medicine, 2020, 52, 702-706.	0.5	1
26	Implementing a "publish, then review" model of publishing. ELife, 2020, 9, .	6.0	25
27	The efficacy and safety of Tipapkinogen Sovacivec therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5â€ years of follow-up. Gynecologic Oncology, 2019, 153, 521-529.	1.4	43
28	Postpartum endometritis and infection following incomplete or complete abortion: Case definition & guidelines for data collection, analysis, and presentation of maternal immunization safety data. Vaccine, 2019, 37, 7585-7595.	3.8	22
29	Determinants of Acquisition and Clearance of Human Papillomavirus Infection in Previously Unexposed Young Women. Sexually Transmitted Diseases, 2019, 46, 663-669.	1.7	10
30	Influencers and preference predictors of HPV vaccine uptake among US male and female young adult college students. Papillomavirus Research (Amsterdam, Netherlands), 2018, 5, 114-121.	4.5	29
31	Examining Feasibility and Support in Prescribing a Plant-based Diet to Patients with Chronic Diseases in a Primary Care Practice. Alternative & Integrative Medicine, 2018, 07, .	0.1	0
32	Optimizing Womenâ€™s Health in Primary Care. Primary Care - Clinics in Office Practice, 2018, 45, xiii-xiv.	1.6	0
33	Will increasing dosing intervals decrease the loss of anti-HPV seropositivity over time?. Vaccine, 2018, 36, 4966.	3.8	1
34	Risk of HPV-16/18 Infections and Associated Cervical Abnormalities in Women Seropositive for Naturally Acquired Antibodies: Pooled Analysis Based on Control Arms of Two Large Clinical Trials. Journal of Infectious Diseases, 2018, 218, 84-94.	4.0	16
35	HPV vaccines â€“ A review of the first decade. Gynecologic Oncology, 2017, 146, 196-204.	1.4	304
36	Evaluation of Type Replacement Following HPV16/18 Vaccination: Pooled Analysis of Two Randomized Trials. Journal of the National Cancer Institute, 2017, 109, djw300.	6.3	43

#	Article	IF	Citations
37	Hypothesis generating data â€“ HPV vaccines â€“ A decade in review. Gynecologic Oncology Reports, 2017, 22, 115-116.	0.6	0
38	Incidence and duration of type-specific human papillomavirus infection in high-risk HPV-naÃ¯ve women: results from the control arm of a phase II HPV-16/18 vaccine trial. BMJ Open, 2016, 6, e011371.	1.9	34
39	Screening for Chronic Obstructive Pulmonary Disease. JAMA - Journal of the American Medical Association, 2016, 315, 1372.	7.4	166
40	Associations between prior HPV4 vaccine doses and cervical cancer screening participation. Cancer Epidemiology, 2016, 42, 108-114.	1.9	13
41	Human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for the prevention of cervical cancer and HPV-related diseases. Expert Review of Vaccines, 2016, 15, 367-387.	4.4	46
42	Pathways to preterm birth: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine, 2016, 34, 6093-6101.	3.8	13
43	Screening for Syphilis Infection in Nonpregnant Adults and Adolescents. JAMA - Journal of the American Medical Association, 2016, 315, 2321.	7.4	104
44	Screening for Colorectal Cancer. JAMA - Journal of the American Medical Association, 2016, 315, 2564.	7.4	1,725
45	Progression of HPV infection to detectable cervical lesions or clearance in adult women: Analysis of the control arm of the VIVIANE study. International Journal of Cancer, 2016, 138, 2428-2438.	5.1	80
46	No evidence in US of HPV16/18 cancer precursor reduction. Vaccine, 2016, 34, 200.	3.8	1
47	Adherence to cervical cancer screening varies by human papillomavirus vaccination status in a high-risk population. Preventive Medicine Reports, 2015, 2, 711-716.	1.8	21
48	Post Hoc Analysis of the PATRICIA Randomized Trial of the Efficacy of Human Papillomavirus Type 16 (HPV-16)/HPV-18 AS04-Adjuvanted Vaccine against Incident and Persistent Infection with Nonvaccine Oncogenic HPV Types Using an Alternative Multiplex Type-Specific PCR Assay for HPV DNA. Vaccine Journal, 2015, 22, 235-244.	3.1	16
49	IIV3 reduced flu in HIVâˆ’ pregnant women and infants, and in HIV+ pregnant women but not their infants. Annals of Internal Medicine, 2015, 162, JC6.	3.9	0
50	Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials. Lancet Oncology, The, 2015, 16, 775-786.	10.7	247
51	Response to philanthropic support of HPV vaccination efforts. Preventive Medicine, 2015, 76, 127-128.	3.4	0
52	Incorporating Osteopathic Curriculum Into a Family Medicine Residency. Family Medicine, 2015, 47, 794-8.	0.5	2
53	Quantifying the Decisional Satisfaction to Accept or Reject the Human Papillomavirus (HPV) Vaccine: A Preference for Cervical Cancer Prevention. PLoS ONE, 2014, 9, e88493.	2.5	9
54	Women Have a Preference for Their Male Partner to Be HPV Vaccinated. PLoS ONE, 2014, 9, e97119.	2.5	8

#	Article	IF	Citations
55	In a Safety Net Population HPV4 Vaccine Adherence Worsens as BMI Increases. PLoS ONE, 2014, 9, e103172.	2.5	5
56	Positive High-Risk HPV Test with Negative Cytologyâ€"A Conundrum and Blessing of Our Latest Technology. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 10-11.	2.5	0
57	Conclusions About the Quadrivalent Human Papillomavirus Vaccine Efficacy Based on Alternate Dosing Schedules and Less Than Three Dose Immunogenicity is Inappropriate. Journal of Infectious Diseases, 2014, 210, 330-331.	4.0	1
58	Primary Strategies for HPV Infection and Cervical Cancer Prevention. Clinical Obstetrics and Gynecology, 2014, 57, 256-278.	1.1	30
59	Reduction in HPV Prevalence--No Evidence to Support HPV Vaccination reduces HPV Prevalence. Journal of Infectious Diseases, 2014, 209, 1302-1304.	4.0	1
60	The influence of free quadrivalent human papillomavirus vaccine (HPV4) on the timely completion of the three dose series. Preventive Medicine, 2014, 61, 20-25.	3.4	15
61	Urban and Rural Safety Net Health Care System Clinics: No Disparity in HPV4 Vaccine Completion Rates. PLoS ONE, 2014, 9, e96277.	2.5	2
62	Cross protection against HPV might prevent type replacement. Lancet Infectious Diseases, The, 2013, 13, 195.	9.1	8
63	Speculation overinflates long-term efficacy of vaccine for anal dysplasia. Lancet Oncology, The, 2013, 14, e249-e250.	10.7	0
64	Efficacy of the HPV-16/18 AS04-Adjuvanted Vaccine Against Low-Risk HPV Types (PATRICIA Randomized) Tj ETQq0 0 0 rgBT /Overlock 1	4.0	73
65	RE: Annual Report to the Nation on the Status of Cancer, 1975-2009, Featuring the Burden and Trends in Human Papillomavirus (HPV)-Associated Cancers and HPV Vaccination Coverage Levels and RE: Inequalities in Human Papillomavirus (HPV)-Associated Cancers: Implications for the Success of HPV Vaccination. Journal of the National Cancer Institute, 2013, 105, 749-750.	6.3	11
66	Review: Combined oral contraceptives are associated with venous thrombosis. Annals of Internal Medicine, 2013, 159, JC12.	3.9	1
67	Review: Yoga reduces low back pain and back-specific disability. Annals of Internal Medicine, 2013, 159, JC13.	3.9	0
68	Quantifying Clinical HPV4 Dose Inefficiencies in a Safety Net Population. PLoS ONE, 2013, 8, e77961.	2.5	6
69	Predictors of Three Dose On-Time Compliance with HPV4 Vaccination in a Disadvantaged, Underserved, Safety Net Population in the US Midwest. PLoS ONE, 2013, 8, e71295.	2.5	16
70	Long-Term Follow-Up of HPV16-Positive Women: Persistence of the Same Genetic Variant and Low Prevalence of Variant Co-Infections. PLoS ONE, 2013, 8, e80382.	2.5	11
71	Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncology, The, 2012, 13, 100-110.	10.7	432
72	Prevalence and risk factors for cervical HPV infection and abnormalities in young adult women at enrolment in the multinational PATRICIA trial. Gynecologic Oncology, 2012, 127, 440-450.	1.4	55

#	Article	IF	Citations
73	Prophylactic HPV Vaccines and Prevention of Cervical Intraepithelial Neoplasia. Current Obstetrics and Gynecology Reports, 2012, 1, 95-105.	0.8	8
74	Prevention of HPV-Associated Diseases in the United States. , 2012, , 211-255.		0
75	3q26 Amplification Is an Effective Negative Triage Test for LSIL: A Historical Prospective Study. PLoS ONE, 2012, 7, e39101.	2.5	10
76	Efficacy of the human papillomavirus (HPV)â€16/18 AS04â€adjuvanted vaccine in women aged 15â€"25 years with and without serological evidence of previous exposure to HPVâ€16/18. International Journal of Cancer, 2012, 131, 106-116.	5.1	109
77	Who should be targeted for vaccination against anal cancer?. Lancet Oncology, The, 2011, 12, 828-829.	10.7	6
78	Next Generation Cancer Protection: The Bivalent HPV Vaccine for Females. ISRN Obstetrics & Gynecology, 2011, 2011, 1-20.	1.2	27
79	HPV Vaccine against HPV Infection and Disease in Males. New England Journal of Medicine, 2011, 364, 2163-2165.	27.0	5
80	Review of Gardasil. Journal of Vaccines & Vaccination, 2010, 01, .	0.3	22
81	Cervical cancer incidence can increase despite HPV vaccination. Lancet Infectious Diseases, The, 2010, 10, 594-595.	9.1	38
82	Prophylactic HPV vaccines: current knowledge of impact on gynecologic premalignancies. Discovery Medicine, 2010, 10, 7-17.	0.5	49
83	Smoking Enhances Risk for New External Genital Warts in Men. International Journal of Environmental Research and Public Health, 2009, 6, 1215-1234.	2.6	19
84	Clinical diagnosis of vaginitis was moderately accurate in symptomatic women. Evidence-Based Medicine, 2009, 14, 88-88.	0.6	1
85	Currently approved prophylactic HPV vaccines. Expert Review of Vaccines, 2009, 8, 1663-1679.	4.4	133
86	Prevention of Human Papillomavirus Infections and Associated Diseases by Vaccination: A New Hope for Global Public Health. Public Health Genomics, 2009, 12, 319-330.	1.0	31
87	GardasilÂ®needs a new consent form. Expert Review of Vaccines, 2009, 8, 1613-1614.	4.4	2
88	Preliminary HPV vaccine results for women older than 25 years. Lancet, The, 2009, 373, 1921-1922.	13.7	22
89	Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6Â·4 years. Lancet, The, 2009, 374, 1975-1985.	13.7	328
90	Cervico-Isthmic Corporeal Pregnancy With Delivery at Term: A Review of the Literature With a Case Report. Obstetrical and Gynecological Survey, 2009, 64, 335-344.	0.4	24

#	Article	IF	Citations
91	Current prophylactic HPV vaccines and gynecologic premalignancies. Current Opinion in Obstetrics and Gynecology, 2009, 21, 457-464.	2.0	24
92	Impact of vaccination with Cervarixâ„¢ on subsequent HPV-16/18 infection and cervical disease in women 15â€“25Âyears of age. Gynecologic Oncology, 2008, 110, S11-S17.	1.4	62
93	Human Papillomavirus Types 16 and 18 Vaccine (Recombinant, AS04 Adjuvanted, Adsorbed) [Cervarix???]. Drugs, 2008, 68, 359-372.	10.9	81
94	Age for HPV vaccination. Vaccine, 2008, 26, A7-A11.	3.8	26
95	Human Papillomavirus Types 16 and 18 Vaccine (Recombinant, AS04 Adjuvanted, Adsorbed) [Cervarix???]???. BioDrugs, 2008, 22, 205-208.	4.6	11
96	Prophylactic human papillomavirus vaccines to prevent cervical cancer: review of the Phase II and III trials. Therapy: Open Access in Clinical Medicine, 2008, 5, 313-324.	0.2	15
97	Human papillomavirus and HPV vaccines: a review. Bulletin of the World Health Organization, 2007, 85, 719-726.	3.3	297
98	Noninferiority of Antibody Response to Human Papillomavirus Type 16 in Subjects Vaccinated with Monovalent and Quadrivalent L1 Virus-Like Particle Vaccines. Vaccine Journal, 2007, 14, 792-795.	3.1	35
99	The Effect of Oral Contraceptives on Bone Mass and Stress Fractures in Female Runners. Medicine and Science in Sports and Exercise, 2007, 39, 1464-1473.	0.4	117
100	Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet, The, 2007, 369, 1693-1702.	13.7	579
101	Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet, The, 2007, 369, 2161-2170.	13.7	1,153
102	Quadrivalent Vaccine against Human Papillomavirus to Prevent Anogenital Diseases. New England Journal of Medicine, 2007, 356, 1928-1943.	27.0	1,741
103	American Cancer Society Guideline for Human Papillomavirus (HPV) Vaccine Use to Prevent Cervical Cancer and Its Precursors. Ca-A Cancer Journal for Clinicians, 2007, 57, 7-28.	329.8	443
104	Quadrivalent HPV vaccine prevented cervical neoplasia caused by HPV-16 and HPV-18. ACP Journal Club, 2007, 147, 49.	0.1	1
105	Sustained efficacy up to 4Â·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet, The, 2006, 367, 1247-1255.	13.7	1,395
106	Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine, 2006, 24, 5571-5583.	3.8	380
107	Chapter 13: Current findings from prophylactic HPV vaccine trials. Vaccine, 2006, 24, S114-S121.	3.8	120
108	Efficacy of a Bivalent L1 Virus-Like Particle Vaccine in Prevention of Infection With Human Papillomavirus Types 16 and 18 in Young Women: A Randomized Trial. Obstetrical and Gynecological Survey, 2005, 60, 171-173.	0.4	43

#	Article	IF	Citations
109	How condom use, number of receptive anal intercourse partners and history of external genital warts predict risk for external anal warts. International Journal of STD and AIDS, 2005, 16, 203-211.	1.1	11
110	Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncology, The, 2005, 6, 271-278.	10.7	1,400
111	Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control. Vaccine, 2005, 23, 2388-2394.	3.8	187
112	Are we closer to the prevention of HPV-related diseases?. Journal of Family Practice, 2005, Suppl HPV Prevention, S10-6; quiz S23.	0.2	0
113	Magnification and Chromoscopy with the Acetic Acid Test. Endoscopy, 2004, 36, 748-750.	1.8	5
114	Beyond the Pap: Assessing Patients' Priorities for the Annual Examination. Journal of Women's Health, 2004, 13, 791-799.	3.3	11
115	Why Am I Scared of HPV?. Ca-A Cancer Journal for Clinicians, 2004, 54, 245-247.	329.8	34
116	Optical detection of high-grade cervical intraepithelial neoplasia in vivo: results of a 604-patient study. American Journal of Obstetrics and Gynecology, 2004, 190, 1249-1257.	1.3	88
117	Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet, The, 2004, 364, 1757-1765.	13.7	1,435
118	Factors Affecting the Detection Rate of Human Papillomavirus. Annals of Family Medicine, 2003, 1, 221-227.	1.9	41
119	Tampon Samplings With Longer Cervicovaginal Cell Exposures Are Equivalent to Two Consecutive Swabs for the Detection of High-Risk Human Papillomavirus. Sexually Transmitted Diseases, 2002, 29, 628-636.	1.7	31
120	American Cancer Society Guideline for the Early Detection of Cervical Neoplasia and Cancer. Ca-A Cancer Journal for Clinicians, 2002, 52, 342-362.	329.8	782
121	Randomized clinical trial of PCRâ€"determined human papillomavirus detection methods: Self-sampling versus clinician-directedâ€"Biologic concordance and women's preferences. American Journal of Obstetrics and Gynecology, 2002, 186, 365-373.	1.3	104
122	Self-screening methods are the next public health improvement for sexually transmitted infection detection. JAMA Pediatrics, 2002, 156, 1154-5.	3.0	0
123	Healing Experiences After Cervical Cryosurgery. Journal of Lower Genital Tract Disease, 2001, 5, 113-113.	1.9	0
124	Analysis of acetic acid-induced whitening of high-grade squamous intraepithelial lesions. Journal of Biomedical Optics, 2001, 6, 397.	2.6	53
125	Self-reported desire to improve colposcopic impressions. Archives of Gynecology and Obstetrics, 2000, 264, 137-142.	1.7	1
126	Treatment threshold probability for vaginitis. American Journal of Obstetrics and Gynecology, 2000, 183, 517-518.	1.3	1

#	Article	IF	Citations
127	Cost-effectiveness of the Conventional Papanicolaou Test With a New Adjunct to Cytological Screening for Squamous Cell Carcinoma of the Uterine Cervix and Its Precursors. Archives of Family Medicine, 2000, 9, 713-721.	1.2	13
128	Leukocytes in the Cervix. Obstetrics and Gynecology, 1998, 91, 987-992.	2.4	7
129	Colposcopy Quality Control. Journal of Lower Genital Tract Disease, 1998, 2, 195-203.	1.9	29
130	Multi-wavelength Digital Colposcopy to Aid Early Detection of Cervical Cancer. , 1998, , .		1
131	The Efficacy of Topical Benzocaine Gel in Providing Anesthesia Prior to Cervical Biopsy and Endocervical Curettage. Journal of Lower Genital Tract Disease, 1997, 1, 221-227.	1.9	2
132	Is LEEP the Cesarean Delivery of Cervical Intraepithelial Neoplasia?. Journal of Lower Genital Tract Disease, 1997, 1, 257-259.	1.9	0
133	What is a cost-effectiveness analysis?. Archives of Family Medicine, 1997, 6, 527-528.	1.2	0
134	Topical benzocaine: Does it alleviate pain? Who knows?. American Journal of Obstetrics and Gynecology, 1996, 174, 1077.	1.3	0
135	Elastin fibers resembling Sporothrix schenkii in the skin of a patient with acquired immunodeficiency syndrome. Archives of Pathology and Laboratory Medicine, 1995, 119, 744-8.	2.5	1
136	Colposcopy for family physicians. Archives of Family Medicine, 1994, 3, 400-401.	1.2	0
137	Anesthetic blocks for loop electrosurgical excision procedure. Journal of Family Practice, 1994, 39, 249-56.	0.2	6
138	Cervical Cancer Elimination Is Dependent on Women's Self-Tests for Primary Human Papillomavirus Testing Triaged by Methylation Status. Journal of Clinical Oncology, 0, , .	1.6	4
139	US women screen at low rates for both cervical and colorectal cancers than a single cancer: a cross-sectional population-based observational study. ELife, 0, 11, .	6.0	3